皮肤和呼吸道可输出的TRPA1抑制剂
Tomohiro Shirai1, Kazuki Kinoshita2, Kentaro Kumihashi2
1Sensory Science Research, Kao Corporation, 2606 Akabane, Ichikai-machi, Haga, Tochigi, Japan; Degree Programs in Pure and Applied Sciences, Graduate School of Science and Technology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan.
Bioorganic & medicinal chemistry
|June 28, 2024
概括
研究人员在香水中发现了一种强大的TRPA1抑制剂2-甲基-4--1-醇. 这种化合物有效地减少了皮肤和呼吸道的刺激,显示了局部和吸入配方的前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 感官科学 感官科学
- 有机化学 有机化学
背景情况:
- 暂时受体潜在基林1 (TRPA1) 通道与感官刺激有关.
- 鉴定新型TRPA1抑制剂对于开发刺激相关疾病的治疗方法至关重要.
- 香水化合物是生物活性分子的未经探索的来源.
研究的目的:
- 研究香水化合物作为TRPA1抑制剂的来源.
- 确定和描述用于皮肤和呼吸道应用的新型TRPA1抑制剂.
- 评估已识别的抑制剂的结构-活性关系.
主要方法:
- 香水化合物的查TRPA1抑制活性.
- 在体外测试以评估对各种TRPA1激动剂的抑制.
- 评估立体异构体以确定最佳功效.
- 结构与活动关系 (SAR) 研究.
- 在体内测试局部和吸入疗效.
主要成果:
- 发现了2-甲基-4--1-醇 (化合物1),一种强效和选择性的TRPA1抑制剂.
- 化合物1表现出对TRPA1激动剂的广泛抑制.
- 化合物1的特定立体同位素显示出增强的抑制活性.
- 化合物1的局部应用在敏感皮肤模型中减少了感官刺激.
- 吸入化合物1显著减少了氨引起的气道刺激.
结论:
- 香水化合物可以产生有效的TRPA1抑制剂.
- 化合物1是针对TRPA1介导刺激的局部和吸入配方的有希望的候选者.
- 立体选择性合成可以进一步优化化合物1的功效.
- 这些发现支持开发芳香衍生化合物用于治疗感官刺激的治疗应用.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
01:19Antiasthma Drugs: Leukotriene Modifiers
271
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
271
01:22Drug Delivery: Miscellaneous Routes
338
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
338